Posted On: 12/01/2015 10:03:09 PM
Post# of 193
Valeant: All Negative News Already Priced In
Multiple fraud allegations against Valeant have been proven to be unsubstantiated. Right before Thanksgiving, short-sellers moved another attack hoping to bring the price down, but it appears investors don't trust them anymore. Politicians attacking Valeant might have been motivated by personal interests as well.
Valeant Pharmaceuticals International Inc. (NYSE:VRX & TSE:VRX) surged nearly 10% Tuesday, putting it on target for a three-day winning streak and helping the stock to recoup its losses over the past month.
Valeant Pharmaceuticals shares have gained about 40% since falling to a recent closing low of $70.32 on Nov. 17. The stock is now heavily Bullish.
The stock closed $98.78 on Tuesday after gaining nearly 10%.
The average price target for Valeant Pharmaceuticals (NYSE:VRX) is $172 according to NASDAQ Research. Latest NASDAQ’s investor sentiment is 85% BULLISH on VRX .
CNN Money analysts also maintains bullish forecast for Valeant Pharmaceuticals, with some price target reaching as high as $300
Continue reading Valeant Pharmaceuticals
Multiple fraud allegations against Valeant have been proven to be unsubstantiated. Right before Thanksgiving, short-sellers moved another attack hoping to bring the price down, but it appears investors don't trust them anymore. Politicians attacking Valeant might have been motivated by personal interests as well.
Valeant Pharmaceuticals International Inc. (NYSE:VRX & TSE:VRX) surged nearly 10% Tuesday, putting it on target for a three-day winning streak and helping the stock to recoup its losses over the past month.
Valeant Pharmaceuticals shares have gained about 40% since falling to a recent closing low of $70.32 on Nov. 17. The stock is now heavily Bullish.
The stock closed $98.78 on Tuesday after gaining nearly 10%.
The average price target for Valeant Pharmaceuticals (NYSE:VRX) is $172 according to NASDAQ Research. Latest NASDAQ’s investor sentiment is 85% BULLISH on VRX .
CNN Money analysts also maintains bullish forecast for Valeant Pharmaceuticals, with some price target reaching as high as $300
Continue reading Valeant Pharmaceuticals
(0)
(0)
